On May 27, 2026 Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, reported that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29-June 2 in Chicago.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The findings in the poster presentation demonstrate the value of Arima’s Hi-C sequencing-based approach to fusion and rearrangement detection, available clinically through the Aventa FusionPlus test, for identification of clinically actionable driver alterations in patients with non-small cell lung cancer (NSCLC).
Poster Presentation Details:
Poster Board Number: 420
Title: Hi-C Sequencing Can Identify Clinically Actionable Fusions in Non-Small Cell Lung Cancer Missed by Other Sequencing Technologies
Abstract Number: 8630
Date and Time: May 31, 2026, 9:00am-12:00pm CDT
Track: Lung Cancer-Non-Small Cell Metastatic
Presenter: Kevin Levine, M.D., University of Washington/Fred Hutchinson Cancer Center, Seattle, WA.
(Press release, Arima Genomics, MAY 27, 2026, View Source [SID1234666124])